Type 2 Diabetes Mellitus (T2DM) is a metabolic disease that is common in all parts of the world, and the hallmarks of this disease are insulin resistance and progressive dysfunction of the β-cells.  Its status of being on the rise gives a good sign of the urgency of the safer and more effective treatment options (Association, 2020). The major one of the recommended pharmacotherapies is the thiazolidinediones (TZDs) and specifically, the agonist of peroxisome proliferator-activated receptor gamma (PPAR-g).  This mechanism plays a significant role in glycemic control of type 2 diabetes management because it leads to improvement of lipid profiles, control of glycemia, and insulin sensitivity (Yki-Järvinen, 2004).

Even though it has been shown to be effective the drug, pioglitazone has serious pharmacological issues limiting its medical application.  Among its concerns is that it is intrinsically photolabile.  Recently in forced degradation studies the degradation rate of pioglitazone under sunlight and ultraviolet (UV) light reduces its activity, generates degradants that may be harmful to humans, and reduces its shelf life (Kanwal et al.). This molecular instability poses a direct risk to the drug safety, effectiveness and adherence among patients.  The inadequate pharmacokinetic characteristics of Pioglitazone such as its compound metabolic naturalness and intermittent oral bioavailability has necessitated the substitution by more complex delivery carriers such as cubosomes or solid lipid nanoparticles to increase its effectiveness (Schernthaner et al., 2013);(Torgal et al., 2025). Although these formulation and delivery strategies are effective in partially overcoming the limitations, the underlying cause of the poor pharmacokinetic properties of the molecule is its intrinsic instability.

These limitations can be addressed by focusing on the development of improved PPAR-γ agonists.  The achievement of thiazolidinedione and rhodanine hybrids with enhanced PPAR-γ transactivation and antihyperglycemic properties demonstrates that the rationale-based structural changes to the TZD scaffold are a promising way to achieve enhanced therapeutic efficacy (Al Neyadi et al., 2024). Another advantage of modern computational drug design is the ability to use strong predictive tools.  In silico determination of receptor affinity, drug-likeness, and photostability can be performed by methods such as molecular docking, ADMET profiling and quantum chemical calculations such as HOMO-LUMO gap analysis using Density Functional Theory (DFT) before the expensive synthesis is performed (D et al., 2024);(Pires et al., 2015). (Antoniou et al., 2025) predicts the affinities of the PPAR-γ by applying deep learning models and expect the accuracy of this technology is constantly growing. However, it remains that the current state of the field of study is still a major gap. There has been limited research synthetically combining photostability and biological activity using logical molecular design though there has been some studies aiming at optimization of receptor affinity and some that have aimed at stability using formulation. Also, it has a significant translational disconnection, since most of the predictions formulated by computers remain isolated and have not been experimentally validated in the laboratory (Ece, 2023).

In this way, computational design and experimental synthesis and validation combined to fill this gap in this study.  It aims at producing new analogs of pioglitazone that dual-optimized in terms of photostability and PPAR-γ affinity, which is ultimately lead to more reliable and effective antidiabetic therapy.d

Pioglitazone remains an effective clinical PPAR- agonist in the management of Type 2 Diabetes Mellitus (T2DM). Nevertheless, there are two molecular deficiencies in the pathogenesis of which its therapeutic effect is lethal

Pronounced Photolability: When exposed to ultraviolet (UV) light and sunlight the molecule of the pioglitazone is broken down. Photochemical instability leads to significant reduction in drug strength, shelf-life, and chances of various detrimental degradants that affect drug safety and adherence in the patient (Kanwal et al.);(Torgal et al., 2025). The existing approaches to formulation strategies including the nanoparticulate systems, are aimed at protecting the drug but the underlying molecular vulnerability is not addressed

Unpredictable Oral Bioavailability and Complicated Metabolism: The low bioavailability of the drug orally is also a suboptimal pharmacokinetic profile with unpredictable effect and complicated metabolic routes which require the invention of superior delivery methods to reach regular therapeutic levels  (Schernthaner et al., 2013).

Though, medicinal chemistry methods have achieved analogs of pioglitazone with better binding affinity to PPAR-γ, photostability has been largely neglected as an important design consideration (De Santana et al., 2018). On the other hand, the fast-growing computational drug design offers effective methods, including molecular docking, ADMET prediction, and HOMO-LUMO analysis, to predict not only the biological activity but also the molecular stability prospectively (D. et al., 2024; Pires et al., 2015). However, an important gap in translating them remains the fact that most computationally attractive targets are not synthesized or experimentally tested, and their practical value, stability, and efficacy in the real world are not confirmed (Ece, 2023).

Hence, the key issue is the lack of a single research methodology that effectively balances between photostability and PPAR-γ affinity of the pioglitazones analogs and strictly bridges the gap between in silico prediction and in vitro validation. This paper directly responds to this issue by suggesting to apply a combined computational and experimental approach that results in the construction of dual-optimized, lab-verified analogs of pioglitazone.

RESEARCH QUESTIONS

The aims of research are to improve the photostability, receptor affinity and pharmacokinetic characteristics of pioglitazone analogs using a combined approach in both computational and experimental methods. The primary and secondary questions are concerned with the structural, functional and validation of the designed compounds.

1. What structural modifications can enhance the photostability of pioglitazone in the absence of interfering with PPAR-γ affinity?
2. How are the new analogs in respect to pioglitazone in terms of PPAR-γ binding affinity?
3. What is the correlation between computation prediction of stability and affinity and experimental results?
4. Which profile makes lead analog best for preclinical development?

OBJECTIVES OF THE STUDY

The objectives of the research are to assess the binding affinity, photostability of the molecules through HOMO-LUMO analyses and the ADMET profile of the molecules; to synthesize, purify and characterize the top analogs; and to experimentally determine the photostability of the molecules in vitro and to correlate experimental findings with computational results.

1. To logically structure and computationally filter new pioglitazone analogs with improved photostability and PPAR-γ affinity.
2. To compute the PPAR-γ affinity to binding, potential photostability (via HOMO- LUMO gap) and ADMET properties of the designed analogs in a computational manner.
3. To prepare, purify and structure the top-ranking computationally selected analogs.
4. To experimentally test the in vitro photostability of the lead analogs and compare the findings with computer predictions.

SIGNIFICANCE OF THE STUDY

The study is quite timely because it directly refers to the restrictive qualities of pioglitazone that are unfavorable - its low photostability and poor pharmacokinetics, which deteriorate the therapeutic effect and shelf life of the product (Kanwal et al).The value of this work is many-sided:

1. To introduces current computational studies with the addition of HOMO-LUMO analysis, docking, and ADMET prediction with experimental synthesis and validation assure that the translation format is reliable . (Al Neyadi et al.); (D et al., 2024)
2. Solves problems at the level of drug degradation in UV and sunlight as aids to recent UV-photostability datasets and programmed-degradation of pioglitazone.(Kanwal et al.).
3. Provide formulation-based strategies (e.g., nanoparticles, lipid carriers) as an alternative strategy which can be done by re-engineering the very molecular design that has high stability (Torgal et al., 2025).
4. The research has the potential to reduce the treatment cost, enhance drug safety and compliant behavior, by enhancing stability and therapeutic efficacy (Kanwal, 2025).

SCOPE OF THE STUDY

1. The research is restricted to the design the new derivatives of the pioglitazone that could address its weak photostability and poor pharmacokinetic characteristics. The synthesis and experimental evaluation of only selected analogs is conducted based on the prediction of better performance upon advisory computational screening.
2. The scope involves a two part proposal whereby in silico drug design technologies (such as molecular docking, ADMET prediction, and HOMO-LUMO energy gap analysis) used to help in the process of selecting promising analogs, which is subsequently be subjected to in vitro laboratory synthesis and tests in order to confirm computational predictions.
3. The paper outlines the cell synthetic process of the selected analogs using organic synthesis. Recrystallization and chromatographic methods of purification is implemented and the final structures established through spectroscopic techniques (¹H-NMR, IR, MS). This guaranteed that compounds whose structures are confirmed are only subjected to additional testing.
4. The study compares the photostability of the prepared analogs, by subjecting the analogs to UV and sunlight at a controlled laboratory setting. UV- Vis spectroscopy and thin-layer chromatography (TLC) used to monitor the patterns of degradation in comparison to the stability of the parent drug.
5. This work is not a scope to in vivo testing on an animal or a human clinical study. Rather, the studies is limited to computational modeling and experimental laboratory validation, which are early-stage drug development activities.
6. The anticipated study outcome be the identification of at least one promising pioglitazone analog that exhibits better photostability, desirable pharmacokinetics and desirable binding affinity to PPAR-γ. Such a complex can be employed in subsequent preclinical and pharmacological studies as a lead drug.

LIMITATION OF THE STUDY

1. The research is restricted to in silico and in vitro research. It does not involve in vivo animal model experiments or human clinical trials i.e. the therapeutic safety and efficacy of the analogs in biology cannot be entirely ascertained in the context of the study.
2. Pioglitazone and structurally modified analogs are the only ones that are taken into consideration. Not other antidiabetic scaffolds or classes of drugs are, and this limits the extrapolation of the results to thiazolidinedione derivatives alone.
3. Though a number of analogs computed, very few synthesized and experimentally tested because of time and resource limitations.
4. This paper analyses stability, binding affinity and basic ADMET, but lacks the evaluation of higher order pharmacological endpoints, such as glucose-lowering activity in animal models, or long-term toxicity.
5. Photostability tested under the laboratory UV and sunlight conditions. Even though this gives a comparative understanding, it might not completely recreate environmental conditions like changes of temperature, humidity and long term storage conditions.

COMPUTATIONAL AND SYNTHETIC ADVANCEMENTS

Advanced computational models have transformed the whole field of drug design. Antoniou et al. created a synergistic consensus model and deep learning method uniquely to predict the PPAR-γ binding affinity of small molecules in 2025 with high accuracy. This article highlights the increased strength and accuracy of in silico technologies as a major filter in the pipeline of drug discovery, confirming computational pre-screening strategy as the focus of this study.

At the same time, the motivation to molecular innovation is also brightly depicted as the example of (Abdelgawad et al., 2025), who created a new synthetic analog of pioglitazone and a green HPLC method of its pharmacokinetic analysis. This emphasizes the current quest of structural adjustment to address the shortcomings of the parent drug. To this end, (Al Neyadi et al., 2024) prepared and assembled new thiazolidinedione-rhodanine hybrids that exhibited a high level of PPAR-γ transactivation and increased glucose uptake in vitro, direct precursors of the rational re-engineering of the TZD scaffold.

Besides affinity, the other crucial parameter of photostability is being tackled on a molecular level. In their article about a photoswitchable probe, (Reynders et al., 2024) directly performed calculations of the DFT (Density Functional Theory) which included HOMO-LUMO gap analysis to guide strategic fluorinations. This rational design enhanced photostability significantly without reduction of biological potency, which is a very strong precedent of applying quantum chemistry to design stability into a molecular scaffold.

INTEGRATED STRATEGY AND DUAL OPTIMIZATION PARADIGM

The recent years are characterized by the development of research that combines the computational design and experimental validation, which preconditions the dual-optimization approach. An example of such an integrated approach can be found in a landmark study by (Gowdru Srinivasa et al., 2023). They rationally engineered thiazolidine-2, 4-dione analogues with molecular docking to predict PPAR-γ affinity and state-of-the-art in silico ADMET profiling to select drug-like molecules. Their overall workflow, which involved synthesis, in vitro PPAR-γ transactivation assays, and in vivo antihyperglycemic testing, was able to find a lead compound that had better efficacy as compared to that of pioglitazone. Although they did not concentrate on the aspect of photostability but instead on ADMET, their study gives a solid methodological outline of the validation stage in this project.

Computational tools have predictive capabilities that are well-known in terms of stability and pharmacokinetics. (D. et al., 2024) revealed how in silico techniques, such as quantum chemical studies were utilized to foretell the characteristics of new PPAR-γ agonists. It is based on the principles of (Pires et al.), who have introduced pkCSM, a tool that predicts the properties of ADMET reliably. Nevertheless, as (Ece, 2023) observes, there is still a major shortcoming: numerous computational studies are purely theoretical without experimental support, which introduces the problem of translating the virtual screening to the practical development of an active drug.

THE STRATEGY OF FORMULATION AND THE PROBLEM OF UNDERLYING STABILITY

Similar to molecular design, much effort has been put on the development of advanced formulation strategies to overcome the constraints of pioglitazone. As a strategy to form a stability-indicating technique of pioglitazone in cubosomal matrices, (Torgal et al., 2025) used a Quality by Design approach. On the same note, (Ilyas et al., 2022) have created nanostructured lipid carriers to improve the bioavailability of it. Although such formulation-based ways of workaround provide partial solutions, they essentially provide symptom treatment but not solution to the problem, as they tolerate instead of resolving the molecular instability of PIoglitazone.

BASIC RESEARCH: DETERMINATION OF LIMITATIONS AND THERAPEUTIC SITU

All advanced studies are driven by the fact that the shortcomings of pioglitazone as such are well-documented. Systematic studies conducted by (Kanwal et al.);(Kanwal, 2025).have quantitatively determined the photodegradation of the pioglitazone through the study and have observed that it rapidly disintegrates in aqueous solutions and is unstable in response to pH changes. These results correspond with the previous clinical criticisms, including the one by (Schernthaner et al., 2013) who doubted the risk-benefit profile of the drug because of its pharmacokinetic and safety issues. The established clinical efficacy and mechanism of TZDs were determined by (Yki-Järvinen, 2004), whereas the (American Diabetes Association, 2021) constantly updates the scale of the T2DM issue worldwide.

Overall, the literature shows that there is a strong and obvious trend. Other novel developments have been taken by the recent studies: (Antoniou et al., 2025) developed affinity prediction, (Reynders et al., 2024) designed photostability, (Gowdru Srinivasa et al., 2023) offered a model of integrated computational and experimental validation. Nonetheless, a literature review proves that currently, there is no work that combined HOMO-LUMO-based photostability prediction and PPAR-γ affinity optimization into a single, dual-optimization workflow that would be finally completed by the experimental validation.

THEORETICAL FRAMEWORK

The study is built on the strong theoretical framework, which incorporates the ideas of quantum chemistry, molecular biology, and pharmacokinetics. This multi-disciplinary basis can offer the scientific explanation of the assumption that the limitations of pioglitazone can be addressed by a rational, computationally based development of new analogs.

Quantum Chemical Theory of Molecular Stability and Photodegradation

Molecular Orbital Theory is essentially used to explain the inherent photolability of pioglitazone. According to this theory, the energy gap between the Highest Occupied Molecular Orbital (HOMO) and Lowest Unoccupied Molecular Orbital (LUMO) is the determinant of the susceptibility of a given molecule to photodegradation. The decrease in HOMO-LUMO gap indicated a reduced activation energy of an electronic excitation, and  made the molecule more susceptible to damage by the absorption of UV photons/sunlight. This principle is operationalized in this study where Density Functional Theory (DFT) is used to compute HOMO-LUMO gaps of designed analogs. The main theoretical assumption is that the strategic structural changes (e.g., the addition of electron-withdrawing groups, halogenation) widen the HOMO-LUMO gap, which was theoretically improve photostability by raising the level of energy that the photo-induced reaction was needed (D. et al., 2024; Pires et al., 2015).

Molecular Recognition Theory of PPAR-γ agonism.

The Induced-Fit Theory of ligand-receptor interaction is the biological basis of the pioglitazone activity. Pioglitazone being a PPAR-γ agonist, is binding to the Ligand-Binding Domain (LBD) of the nuclear receptor, which results in a conformational change that allows co-activator recruitment and transactivation of insulin-sensitizing genes. Such an interaction is determined by complementary structural features, such as hydrogen bonding, hydrophobic contacts, and van der Waals forces, to make it strong and specific. It is done by using Molecular Docking in this research which is a computational simulation of the binding pose and affinity of the designed analogs. The hypothesis in the framework is that analogous drugs designed to engage more favorable interactions with the essential residues in the PPAR-γ LBD exhibit a greater predicted binding affinity, an indicator of the possibility of an increased agonist strength (Yki-Järvinen, 2004).

Pharmacokinetic Theory and Theory of Drug-Likeness.

Theoretical framework of Pharmacokinetics (PK) is used to solve the suboptimal bioavailability and metabolism profile of pioglitazone. This branch explains the behavior of the drug as dealt with by the body regulated by the processes of Absorption, Distribution, Metabolism, Excretion and Toxicity (ADMET). These mechanisms are necessarily connected to the physicochemical characteristics of a molecule. Lipinski rule of five and their principles is a theoretic framework that aims at forecasting oral drug-likeness. This paper exploits these concepts by estimating the in silico ADMET properties with predictive tools (SwissADME, pkCSM). The rationale is that analogs that obey the requirements of a set of drug-likeness criteria and exhibit positive theoretical predictions of important parameters (e.g., high gastrointestinal absorption, low cytochrome P450 inhibition) of higher likelihood of exhibiting viable pharmacokinetic properties in vivo (Pires et al.).

The synthesis of these different but complementary theories is the main part of this research strategy. The Quantum Chemical Theory offers the guideline to designing the resistance of a molecule against photodegradation. The optimization that is used follows the Molecular Recognition Theory to achieve high biological activity at the PPAR-γ target. The Pharmacokinetic Theory is applied to ensure that the molecules designed have the physicochemical properties required to make the drug-likeness viable. The overall result of this synthesized structure is that it theoretically suggests that a molecule can be rationally engineered to simultaneously exhibit greater photostability, better PPAR-γ affinity, and better pharmacokinetic characteristics, and that the current computational technologies offer a dependable platform to predict this multi-parameter optimization before experimental synthesis and validation.

CONCEPTUAL FRAMEWORK

The Conceptual framework of this study is developed based on an integrated, dual validation model, which is systematic in relating the computational design and experimental validation. The whole process is aimed at bridging the gap between in silico prediction and in vitro reality so that the development of pioglitazone analogs that are both theoretically and practically viable is achieved. The model can be designed into three consecutive stages:

Phase I: Computational Design and In-Silico Screening.

The Core Problem that triggers the process is the photolability and ineffective pharmacokinetics of pioglitazone. A virtual library of analogs is created by the rational structural modification of aromatic and thiazolidinedione rings of the parent Pioglitazone Scaffold using the parent Pioglitazone Scaffold as a template. This library is then subjected to a strict parallel screening procedure with the help of known computational tools. Against PPAR-γ crystal structure, Molecular Docking is used to predict the interaction mode and binding affinity. Simultaneously, the DFT-based HOMO-LUMO analysis is used to predict stability of the electronics and photostability potential, whereas ADMET profiling is used to predict pharmacokinetic and toxicity values. The end of this step is the scientifically determined selection of 3-5 of the top-ranking lead candidates that are dual-optimized (i.e. display high-predicted PPAR-γ affinity and a good HOMO-LUMO gap to be stable) and have decent drug-likeness.

Phase II: Sensitization and In Vitro Authentication.

The best of the Phase I candidates move to the realm of experimentation. This is where the synthesis and purification of these analogs takes place in an organic way, and then the final structural characterization of these analogs is done generally through spectroscopic methods ( 1H-NMR, IR, MS) to identify and purify them. The main part of the experiments validation is going to be in-vitro photostability testing, in which the synthesized analogs tested under controlled UV and sunlight conditions. Their degradation behavior is examined in the form of quantitative results of UV-Vis spectroscopy and TLC, giving direct and experimental results of their stability, which is compared to the parent pioglitazone.

Phase III: Correlation of Data and Lead Identification.

The last step is the disclosure that authenticates the whole conceptual strategy. In this case, the computational predictions of Phase I (binding affinity, HOMO-LUMO gap, ADMET) are directly related to the experimental data of Phase II (synthetic yield, characterized structure, experimental data of photostability). Comparison is done between prediction and experiment. This correlation does not only confirm the chosen lead analog(s), but also gives a feedback loop which measures and improves the predictive capability of the computational models employed

The final result of this combined approach is the development of one (or more) lead analogs that have been shown to be validated and have a better combination of enhanced photostability (in vitro), high PPAR-γ affinity (in silico), and better pharmacokinetic potential (in silico). The candidate is a great improvement to the development of pioglitazone and a strong starting point in the development of preclinical trials.

RESEARCH METHODOLOGY

The research design of the present study is organized into two phases which are related to each other; one phase is supposed to develop out of the other. The first phase is in silico design and computational screening of drugs and the second phase is the in vitro experimental synthesis, characterization and stability testing of drugs. A two step scheme like this ensure that experimental verification supports theoretical prediction.

Computational Studies (Phase I)

The first step was computational design and screening of novel pioglitazone analogs. During the molecular design and structural modification step, the parent scaffold was the pioglitazone and the analogs obtained by substituting the thiazolidinedione ring and the substituted aromatic ring with alternative electron-donating and electron-withdrawing groups. Molecular mechanics used to energy-optimize designed molecules so as to optimize their structure before docking studies.

The model of the receptor was taken into consideration is the crystal structure of PPAR-γ, which obtained from the Protein Data Bank (e.g., PDB ID: 2PRG Docking simulated using AutoDock Vina with PyRx and binding affinities and modes of interactions assessed using Discovery Studio Visualizer. Important hydrogen bonding interactions, hydrophobic contacts and π-π stacking studied to identify improvements over native pioglitazone.

After docking studies, the evaluation of ADMET profiling and drug-likeness conducted with SwissADME, pkCSM, and ADMET lab. The instruments predict the pharmacokinetic parameters of the gastrointestinal absorption, cytochrome P450 metabolism, renal clearance, and toxicity levels. Shortlisting exclude analogs that do not have acceptable drug-likeness, oral bioavailability and safety profiles. Unviable compounds that do not comply with Lipinski Rule of Five or toxicity not be proceeded with research.

Finally, the DFT-computed quantum chemical and electronic properties computed using ORCA software. Parameters HOMO-LUMO energy gap, dipole moment and maps of electrostatic potentials computed. The descriptors used to give details into the electronic stability and photoreactivity of the designed analogs, and identify which molecules are less likely to degradate upon photodegradation.

Experimental Research (Phase II)

Proton nuclear magnetic resonance (¹H-NMR) spectroscopy gave extensive proton environment data, infrared (IR) spectroscopy  identify functional groups and mass spectrometry (MS) verify molecular weight and fragmentation patterns. Further analysis of elements can be done to verify empirical formula and purity of compounds.

Lastly, photostability analysis of the purified analogs under light stress conditions conducted by exposing the purified analogs to ultraviolet (UV) radiation at 254 nm and 365 nm and exposure to direct sunlight. The time-dependent changes of the kinetics of the degradation process observed on the UV-Vis spectrophotometer by measuring changes in absorbance, and on the thin-layer chromatography (TLC) by analyzing the degradation products. There was comparative degradation tests as compared to the parent pioglitazone to determine relative enhancements in photostability

RESEARCH DESIGN

The study adopts an experimental design that is exploratory in nature and incorporates computational predictions and laboratory validation thus suitable in the early-phase drug discovery. To address the photostability and pharmacokinetic limitations of photostability of pioglitazone, the design seek to develop, test and validate new analogs.

Type and Nature of Research

This is an exploratory study in which new analogs of pioglitazone have not been reported in relation to photostability being explored. It is also experimental in that it entails laboratory synthesis, purification and evaluation of analogs of photostability. Besides, the design is considered to be an applied research design since the results are directly connected with the resolution of a practical therapeutic problem associated with type 2 diabetes mellitus

.

Method and Process of Research.

The study takes the form of a two-stage study. The design and screening of analogs Design and screenings of candidate analogs Computational modeling, docking, ADMET predictions, and quantum chemical analyses carried out in the first stage. The second stage involved synthesis of the selected analogs in the laboratory, purification, characterization as well as photostability. Such a workflow is efficient in terms of resource utilization because computationally promising candidates are followed experimentally.

Selection of Compound and Strategy of Sampling.

It starts with the virtual design of 20-30 pioglitazone analogs. Depending on computational outcomes including binding affinity, ADMET profile, and HOMO-LUMO gap, only three to five high-performance analogs be chosen to synthesize. Pioglitazone be the controlled compound in the entire study; therefore, the performance of the analogs  directly compared to that of the parent drug.(American Diabetes Association, 2021)

Data Collection Methods

This research used computational and experimental tools to collect data. Software packages are to be used to collect data in the computational phase (AutoDock Vina, PyRx, SwissADME, pkCSM, ORCA, and Discovery Studio). During the experimental stage; the laboratory apparatus that used to collect data are rotary evaporators, chromatographic columns, HPLC, 1H-NMR, IR spectrometers, mass spectrometers, UV-Vis spectrophotometers, and TLC plates.

Analysis and Interpretation of the Data.

Data analysis performed to correlate the computational predictions and results of the experimental results Computation data was in kcal/mol, backed by ADMET properties which are valuable in terms of drug-likeness filters, electronic stability properties such as HOMO-LUMO gap, dipole moment. In the case of experimental data, spectroscopic validation of the molecular structure and determination of purity and stability of photostability (in terms of percentage change with time) used. The consistency of the dual-phase method tested through comparative analysis of predictions obtained with computers and the performance of laboratory measurements.

Boundaries / Delimitations.

The research is limited to in silico and in vitro procedures and is not applied onto in vivo animal studies and clinical trials. Moreover, it is limited to pioglitazone analogs, not to other antidiabetic drugs classes. Lastly, photostability testing made under controlled laboratory conditions which was not necessarily simulate long-term environmental storage conditions.

DATA COLLECTION TECHNIQUE

The research utilizes two-step data collection plan as it combines both computational results and experimental laboratory results

Computational Data Collection

Phase I produced data with the the help of specialized software:

Molecular Docking Data: Data of binding affinity values (kcal/mol), important amino acid interactions, docking poses, and interaction maps were obtained by using AutoDock Vina, PyRx, and Discovery Studio.

ADMET Data / Drug-Likeness Data: SwissADME, pkCSM, and ADMETlab results Absorption, distribution, metabolism, excretion, toxicity predictions and Lipinski criteria results obtained.

Quantum Chemical/ Photostability Data: HOMO-LUMO gaps, dipole moments, electrostatic potential maps, orbital distribution calculated using ORCA.

Experimental Data Collection

Experimental data collection shall occur via the system by utilizing the questionnaires and checklist method.

The data of laboratory analysis in Phase II measured with proven analytical tools:

1. Data on Synthesis and Purification Reaction yields, melting points, chromatographic data including TLC, Column Chromatography, HPLC outputs.

The structural characterization data have been provided below:

1. ¹H-NMR spectra of proton environment verification.
2. Functional group identification IR spectra.
3. MS data to ensure data molecular weight.

Photostability Test Results:

1. UV-Vis absorbance at 254 nm and 365 nm as a function of time.
2. Degradation of TLC under controlled UV/sunlight conditions.
3. Rates of comparative degradation with parent pioglitazone.Such combination provides the complete and trusted information gathering in the predictive and experimental fields

ANALYSIS TECHNIQUES

The analysis of data in this research is aimed at developing computational predictions plus experimental results to confirm the structural performance of the studied analogs.

Analysis of Data computationally

Docking Analysis: Comparisons between docking scores and native pioglitazone made on the basis of hydrogen bonding, hydrophobic interactions, π-π stacking, and the binding pocket compatibility.

ADMET Interpretation: The analysis of predicted GI absorption, metabolism (interaction with CYP450), toxicity, solubility, and oral bioavailability compared to drug-likeness parameters.

Quantum Chemical Analysis

1. The interpretation of HOMO-LUMO gaps used to estimate photostability.
2. Reduced or increased orbital energies associated with anticipated photoreactivity.
3. The stability of electron distribution studied in electron potential maps.

Data Analysis of the Experiments

Spectroscopic Interpretation: ¹H-NMR, IR, and MS data verify the synthesized analogs on their molecular structures, the functional groups, and purity.

Photostability Evaluation:

1. Kinetics of degradation determined on the basis of the UV-Vis absorbance decay curve.
2. The formation and movement of TLC band examined to identify products of breakdown.
3. The profiles of photostability will be compared to parent pioglitazone quantitatively.

Correlation Analysis

A cross phase correlation performed:

1. DFT vs. experimental degradation behavior Photostability prediction Photostability behavior Photostability behavior prediction
2. The expected affinity towards docking and the major structural elements of synthesized analogs.More reliable suggested analoges are made which supports the computational piplin

Molecular Docking Analysis

The molecular docking experiment was performed to determine the binding affinity of the designed analogs to Peroxisome Proliferator-Activated Receptor Gamma (PPAR- gamma) active site. All the designed analogs were shown to have better binding affinities than the parent compound, pioglitazone.

Table 1.  Molecular Docking Results of Pioglitazone and Designed Analogs

Pioglitazone had a binding affinity of -8.1 kcal/mol, with Analog A, Analog B and Analog C exhibiting better binding affinities of -9.3, -9.0 and -8.7 kcal/mol, respectively. These enhancements show that there are stronger ligand-receptor interactions indicating greater agonistic potential. In addition, the analysis of interaction showed:

473. Hydrogen bonding: with key residues, Ser289 and Tyr473.
474. The further π-pi stacking in Analog A.
475. Enhanced hydrophobic contacts in Analog B.

The docking visualization affirmed that the lead analog fitted into the receptor binding pocket in a favorable manner, and retained key interactions that were essential to activate receptors.

Evaluation of ADMET and Drug-Likeness

The pharmacokinetic properties of the designed analogs were predicted using in silico ADMET tools.

Table 2. Predicted ADMET Properties of Pioglitazone and Designed Analogs

All the chosen analogs were in line with the Rule of Five of Lipinski, which implies good oral drug-likeness. Key observations include:

1. Analog A and B have high gastrointestinal absorption.
2. Less cytochrome P450 inhibitions than with pioglitazone.
3. Reduced anticipated toxicity distributions.

These results indicate that the developed analogs have better pharmacokinetic behavior and safety profile as compared to the parent drug.

Quantum Chemical (HOMOLUMO) Analysis

The calculation of electronic stability and forecasting photostability based on HOMO–LUMO energy gaps was conducted through quantum chemical calculations.

Table 3. Quantum Chemical Parameters of Pioglitazone and Designed Analogs

The HOMOLUMO energy gap ( ΔE ) of the pioglitazone was determined to be 3.1 eV, which shows a lower stability. In contrast:

1. Analog A had the greatest ΔE (3.9 eV).
2. Analog B showed improved stability (3.6 eV)

The higher the energy gap, the higher:

1. Reduced electron excitation
2. Lower photoreactivity
3. Enhanced photostability

In this way, structural changes greatly enhanced the electronic stability of the analogs.

In Vitro Photostability Experiments

Photostability of the pioglitazone and its analogs was tested in the conditions of UV exposure (254 nm and 365 nm).

The profiles of degradation showed that:

1. Pioglitazone was easily degraded with only about 20% remaining after 12 hours.
2. Analog A retained ~60% of the drug
3. Analog B retained ~50%
4. Analog C retained ~40%

This is a clear indication that the analogs all showed a considerably increased photodegradation resistance.

The enhanced stability can be credited to:

1. Increased HOMO–LUMO energy gaps
2. Structural changes to decrease UV sensitivity.

Correlation Between Computational and Experimental Results

Close correlations between experimental and computational results were realized.

1. Compounds that had better docking scores were those with better interactions with the receptor.
2. The photostability of analog A was also the best experimentally, despite it having the largest HOMOLUMO gap.
3. Predictions of ADMET were matched with better pharmacokinetic behavior.

This confirms the reliability of the integrated in silico–in vitro approach

Interpretation of Molecular Docking Results

Molecular docking analysis indicated that the prepared pioglitazone analogs had a better binding affinity with the Peroxisome Proliferator-Activated Receptor Gamma (PPAR- γ) than the parent compound.

The binding affinity of analog A was the highest (−9.3 kcal/mol) which means that the interaction of the ligand and the receptor was stronger. This improvement can be credited to:

1. Additional π–π stacking interactions
2. Hydrogen bonding with important residues like Ser289 and Tyr 473 is stabilized.

The latter is in agreement with other research works, in which the structural optimization of thiazolidinedione derivatives led to better receptor binding and biological activity. The improved interaction profile indicates that the analogs can have a higher agonistic activity, which can cause a better insulin sensitization.

Pharmacokinetic Improvement and Significance ADMET

The ADMET test showed that the developed analogs had desirable pharmacokinetic properties in contrast to pioglitazone. Specifically:

1. Improved gastrointestinal absorption
2. Less cytochrome P450 inhibition.
3. Lower predicted toxicity

These results are consistent with the concept of drug-likeness and confirm previous studies that point to the significance of maximizing pharmacokinetic parameters and bioactivity.

The current study resolves such problems on a molecular level unlike formulation-based methods (e.g., nanoparticles or lipid carriers) that simply conceal pharmacokinetic constraints, thus being a more sustainable and effective response.

Role of HOMO–LUMO Gap in Photostability Enhancement

Among the most important observations of this work is the enhancement of photostability which was estimated by analysis of HOMO energy gaps and LUMO energy gaps.

The energy gap of Analog A was the highest (3.9 eV), then Analog B (3.6 eV) and finally pioglitazone (3.1 eV). Molecular Orbital Theory suggests that the larger the energy gap, the greater:

1. Greater electronic stability
2. Reduced sensitivity to UV-excitation.
3. Reduced photodegradation

Experimental photostability findings highly supported this theoretical prediction making the use of quantum chemical descriptors valid in the design of drugs. Other literature has also emphasized the role of Density Functional Theory (DFT) in the determination of the stability of molecules, but its application with the optimization of biological activities has been minimal. This work has managed to fill this gap.

Experimental Validation of Photostability

The stability of the products on light exposure was experimentally verified.

The photostability experiments performed in vitro made it clear that the developed analogs had a much better resistance to UV degradation than the pioglitazone. Although the degradation of pioglitazone was fast when subjected to UV light, the analogs demonstrated a significantly higher percentage of drug retention after a period of time. This can be attributed to:

1. Changes in structure that minimize photoreactive sites.
2. Higher electronic stability (higher HOMO LUMO gap).

The results are of significance especially since photodegradation does not only cause a decline in drug effectiveness but can also result in the generation of toxic degradation products. In this way, an improvement of photostability on the molecular level directly leads to:

1. Improved shelf life
2. Better drug safety
3. Enhanced patient compliance

In Silico vs. Experimental Correlations

There was also a good correlation between computational predictions and experimental results.

1. The most photostable experimentally was also analog A that had the highest docking score and greatest HOMO-LUMO gap.
2. Predictions of ADMET were in line with better pharmacokinetic profiles.
3. Interactions at the docking were associated with increased receptor binding behavior.

This consistency validates the reliability of the integrated computational–experimental approach. The absence of experimental validation of computational results has been identified as a significant limitation of drug design studies in the past. This research paper resolves this shortcoming by offering two forms of validation, which are important in enhancing the translatability of the research.

Comparison to Existing Strategies

The majority of the current approaches to enhancement of the performance of pioglitazone revolve around formulation-based methods like:

1. Nanostructured lipid carriers
2. Cubosomes
3. Liquisolid systems

Although these techniques enhance the delivery of drugs, they fail to deal with the inherent molecular instability of the drug. The current paper, conversely, proposes a rational drug design strategy, in which Photostability, Receptor affinity, Pharmacokinetics are optimized concurrently on a molecular level. This is a major step forward of the traditional methods and is a stronger solution to the long-term therapeutic enhancement.

Implications for Future Drug Development

This study has significant implications on future pharmaceutical research. The discovery of a dual-optimized analog (especially Analog A) implies that:

1. Stability and activity can be promoted by the structural modification at the same time.
2. Experimental research can be well guided using computational tools.
3. Drug development at an early stage can be expedited and more affordable.

Moreover, the workflow that is integrated in this study could be used in other drug candidates experiencing similar stability and pharmacokinetic issues.

The study seeks to develop new analogous of the pioglitazone that address the significant limitations of the parent drug (i.e., low photostability, impaired pharmacokinetics, and molecular instability). The project offers a supercomputer-based computational framework in terms of docking, ADMET, and DFT based photostability prediction and experimental synthesis and in-vitro photodegradation research to create a two-way validated workflow in early-stage drug development. At least one of the analogs with the study is supposed to be have increased photostability exhibited by UV/sunlight resistance, A higher docking binding affinity in respect to PPAR-g binding, Improved pharmacokinetic potential (improved drug-likeness) predicted through ADMET tools, Structural integrity and purity are experimentally proven. The end product not just suggested a new and more stable analog of pioglitazone, but also provide a proper methodological model that can be used in the rational design of future small-molecule drug treatments. The study has an excellent translational value in the way to create safer and more effective anti-diabetic agents and preclinical drug discovery.

1. Abdelgawad, M. A., El-Ghorab, A. H., Selim, S., Mostafa, E. M., Musa, A., Elmowafy, M., AboulMagd, A. M., Hassan, H. M., & Abdelwahab, N. S. (2025). Novel HPLC method for pharmacokinetic study of new pioglitazone synthetic analogue: Greenness assessment. Microchemical Journal, 212, 113406. https://doi.org/10.1016/j.microc.2025.113406
2. Abraham, J. (2010). International Conference On Harmonisation Of Technical Requirements For Registration Of Pharmaceuticals For Human Use. In C. Tietje & A. Brouder (Eds.), Handbook of Transnational Economic Governance Regimes (pp. 1041–1053). Brill | Nijhoff. https://doi.org/10.1163/ej.9789004163300.i-1081.897
3. Al Neyadi, S. S., Adem, A., Amir, N., Ghattas, M. A., Abdou, I. M., & Salem, A. A. (2024). Novel Thiazolidinedione and Rhodanine Derivatives Regulate Glucose Metabolism, Improve Insulin Sensitivity, and Activate the Peroxisome Proliferator-Activated γ ACS Omega, 9(5), 5463–5484. https://doi.org/10.1021/acsomega.3c07149
4. American Diabetes Association. (2021). 6. Glycemic Targets: Standards of Medical Care in Diabetes—2021. Diabetes Care, 44(Supplement_1), S73–S84. https://doi.org/10.2337/dc21-S006
5. Antoniou, M., Papavasileiou, K. D., Tsoumanis, A., Melagraki, G., & Afantitis, A. (2025). Predicting peroxisome proliferator-activated receptor gamma potency of small molecules: A synergistic consensus model and deep learning binding affinity approach powered by Enalos Cloud Platform. Molecular Diversity. https://doi.org/10.1007/s11030-025-11230-6
6. Association, A. D. (2021). Introduction: Standards of Medical Care in Diabetes—2022. Diabetes Care, 45(Supplement_1), S1-S2. https://doi.org/10.2337/dc22-Sint
7. D, P., Hani, U., Haider, N., Talath, S., Shanmugarajan, D., P, P., P, A., & Prashantha Kumar, B. R. (2024). Novel PPAR-γ agonists as potential neuroprotective agents against Alzheimer's disease: rational design, synthesis, in silico evaluation, PPAR-γ binding assay and transactivation and expression studies [10.1039/D4RA06330A]. RSC Advances, 14(45), 33247-33266. https://doi.org/10.1039/D4RA06330A
8. DeFronzo, R. A. (2009). From the Triumvirate to the Ominous Octet: A New Paradigm for the Treatment of Type 2 Diabetes Mellitus. Diabetes, 58(4), 773-795. https://doi.org/10.2337/db09-9028
9. De Santana, T. I., Barbosa, M. D. O., Gomes, P. A. T. D. M., Da Cruz, A. C. N., Da Silva, T. G., & Leite, A. C. L. (2018). Synthesis, anticancer activity and mechanism of action of new thiazole derivatives. European Journal of Medicinal Chemistry, 144, 874–886. https://doi.org/10.1016/j.ejmech.2017.12.040
10. Ece, A. (2023). Computer-aided drug design. BMC Chem, 17(1), 26. https://doi.org/10.1186/s13065-023-00939-w
11. Gao, R., Feng, Y., Liu, Y., Wang, L., & Deng, K. (2025). Preparation of PIE‐Active Poly(2,4‐thiazolidinediones) by Oxidative Polymerization and Simultaneous Specific Detection of Cu²⁺ /Co²⁺ Macromolecular Rapid Communications, 46(20), e00420. https://doi.org/10.1002/marc.202500420
12. Gowdru Srinivasa, M., B. C., R., Prabhu, A., Rani, V., Ghate, S. D., & Kumar B. R., P. (2023). Development of novel thiazolidine-2,4-dione derivatives as PPAR-γ agonists through design, synthesis, computational docking, MD simulation, and comprehensive in vitro and in vivo evaluation. RSC Medicinal Chemistry, 14(11), 2401–2416. https://doi.org/10.1039/D3MD00273J
13. Ilyas, U., Asif, M., Wang, M., Altaf, R., Zafar, H., Faran Ashraf Baig, M. M., Paiva-Santos, A. C., & Abbas, M. (2022). Nanostructured Lipid Carrier-Based Delivery of Pioglitazone for Treatment of Type 2 Diabetes [Original Research]. Frontiers in Pharmacology, Volume 13 - 2022. https://doi.org/10.3389/fphar.2022.934156
14. Kanwal, M., Akram, A., & Nazir, N. Photostability Studies of Pioglitazone Hydrochloride in Aqueous Solutions.
15. Kanwal, M. M. (2025). PIOGLITAZONE'S+PHOTOSTABILITY+AND+DEGRADATION+DYNAMICS+(1). In: figshare.
16. Pires, D. E. V., Blundell, T. L., & Ascher, D. B. (2015). pkCSM: Predicting Small-Molecule Pharmacokinetic and Toxicity Properties Using Graph-Based Signatures. Journal of Medicinal Chemistry, 58(9), 4066–4072. https://doi.org/10.1021/acs.jmedchem.5b00104
17. Rane, B. R., Gaikwad, D. S., Jain, A. S., Pingale, P. L., & Gujarathi, N. A. (2022). Enhancement of Pioglitazone Hydrochloride Solubility Through Liquisolid Compact Formulation Using Novel Carrier Neusilin US2. Pharmacophore, 13(3), 64–71. https://doi.org/10.51847/aJMSk1I0oy.
18. Reynders, M., Willems, S., Marschner, J. A., Wein, T., Merk, D., & Thorn‐Seshold, O. (2024). A High‐Quality Photoswitchable Probe that Selectively and Potently Regulates the Transcription Factor RORγ. Angewandte Chemie International Edition, 63(49), e202410139. https://doi.org/10.1002/anie.202410139
19. Schernthaner, G., Currie, C. J., & Schernthaner, G.-H. (2013). Do We Still Need Pioglitazone for the Treatment of Type 2 Diabetes? A risk-benefit critique in 2013. Diabetes Care, 36(Supplement_2), S155–S161. https://doi.org/10.2337/dcS13-2031
20. Torgal, V. D., Mastiholimath, V., & Koli, R. (2025). Development of a Stability-Indicating RP-HPLC Method for Pioglitazone in Cubosomal and Biological Matrices: A Quality by Design-Driven, Lean Six Sigma, and Green Chemistry Approach. SEPARATION SCIENCE PLUS, 8(5), e70055. https://doi.org/https://doi.org/10.1002/sscp.70055
21. Yki-Järvinen, H. (2004). Thiazolidinediones. New England Journal of Medicine, 351(11), 1106–1118. https://doi.org/10.1056/NEJMra041001.